Structure-based design of a potent and selective small peptide inhibitor of Mycobacterium tuberculosis 6-hydroxymethyl-7, 8-dihydropteroate synthase: a computer modelling approach.
In an attempt to design novel anti-TB drugs, the target chosen is the enzyme 6-hydroxymethyl-7,8-dihydropteroate synthase (DHPS), which is an attractive target since it is present in microorganisms but not in humans. The existing drugs for this target are the sulfa drugs, which have been used for about seven decades. However, single mutations in the DHPS gene can cause resistance to sulfa drugs. Therefore, there is a need for the design of novel drugs. Based on the recently determined crystal structure of Mycobacterium tuberculosis (M.tb) DHPS complexed with a known substrate analogue, and on the crystal structures of E. coli DHPS and Staphylococcus aureus DHPS, we have identified a dipeptide inhibitor with the sequence WK. Docking calculations indicate that this peptide has a significantly higher potency than the sulfa drugs. In addition, the potency is 70-90 times higher for M.tb DHPS as compared to that for the pterin and folate-binding sites of key human proteins. Thus, the designed inhibitor is a promising lead compound for the development of novel antimycobcaterial agents.
Rao
Gita Subba
GS
Department of Biophysics, All India Institute of Medical Sciences, New Delhi 110029, India. gitarao@aiims.ac.in
Kumar
Manoj
M
D000995:Antitubercular Agents / Q000737:chemistry* / Q000494:pharmacology; D003198:Computer Simulation; D004094:Dihydropteroate Synthase / Q000037:antagonists & inhibitors*; D004151:Dipeptides / Q000737:chemistry / Q000494:pharmacology; D015195:Drug Design; D004791:Enzyme Inhibitors / Q000737:chemistry / Q000494:pharmacology; D008958:Models, Molecular; D009169:Mycobacterium tuberculosis / Q000187:drug effects* / Q000201:enzymology; D011485:Protein Binding; D013329:Structure-Activity Relationship
D000995:Antitubercular Agents; D004151:Dipeptides; D004791:Enzyme Inhibitors; D004094:Dihydropteroate Synthase